

CORRECTED COPY

MATERIALS LICENSE

Amendment No. 43

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s); and to import such byproduct and source material. This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

"OFFICIAL RECORD COPY"

Licensee		In accordance with application dated April 19, 1984,	
1. United Hospitals of Newark Presbyterian Hospital Unit		3. License number 29-01423-01 is amended	
2. 15 South Ninth Street Newark, New Jersey 07107		in its entirety to read as follows:	
		4. Expiration date March 31, 1990	
		5. Docket or Reference No. 030-02435	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.	
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.	
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.	
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.	
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 1000 millicuries total for sources authorized in Subitem 6.E.	
F. Xenon 133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 300 millicuries	

8507030568 850611
REG1 LIC30
29-01423-01 PDR

ML10

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

29-01423-01

Docket or Reference number

030-02435

CORRECTED COPY

Amendment No. 43

(continued)

- | | | |
|---|----------------------------------|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
|---|----------------------------------|--|

- | | | |
|-----------------|---|-------------------|
| G. Strontium 90 | G. Sealed source (Tracerlab Model RA-1) | G. 50 millicuries |
|-----------------|---|-------------------|

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- F. Blood flow and pulmonary function studies.
- G. For treatment of superficial eye disease.

CONDITIONS

- 10. Licensed material shall be used only at United Hospitals of Newark, Presbyterian Hospital Unit, 15 South Ninth Street, Newark, New Jersey.
- 11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions, and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
- 12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

- | | |
|-------------------------|--|
| Arnold I. Brenner, D.O. | Groups I, II, and III
Iodine 131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
Xenon 133
Phosphorus 32 as soluble phosphate of treatment of polycythemia vera, leukemia and bone metastases |
| William C. Cham, M.D. | Group VI
Strontium 90 for treatment of superficial eye conditions
Depleted uranium for shielding |
| Joseta del Carmen, M.D. | Groups IV, V, and VI
Strontium 90 for treatment of superficial eye conditions
Depleted uranium for shielding |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

29-01423-01

Docket or Reference number

030-02435

CORRECTED COPY

Amendment No. 43

(12. continued)

CONDITIONS

Wade N. Miller, M.D.

Groups I, II, III and IV

Xenon 133

Iodine 131 for treatment of thyroid carcinoma

James M. Brown, M.D.

Strontium 90 for treatment of superficial eye conditions

Mary Natrella, M.D.

Groups I, II, III and IV

Xenon 133

Iodine 131 for treatment of thyroid carcinoma

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

14. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

- (a) Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
- (b) Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- (c) Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for the inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

15. Sealed sources containing licensed material shall not be opened.

16. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 30 millicuries or less.

17. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

29-01423-01

Docket or Reference number

030-02435

CORRECTED COPY

Amendment No. 43

(continued)

CONDITIONS

18. A. Each sealed source containing licensed material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, a sealed source received from another person shall not be put into use until tested.
- B. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which the sealed source is permanently mounted or stored on which one might expect contamination to accumulate. Records of leak test results shall be kept in units of microcuries and maintained for inspection by the Commission.
- C. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated and repaired or to be disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the test with the U. S. Nuclear Regulatory Commission, Region I, 631 Park Avenue, King of Prussia, Pennsylvania 19406, describing the equipment involved, the test results, and the corrective action taken.
- D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically authorized by the Commission or an Agreement State to perform such services.
19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated April 19, 1984; letters dated June 24, 1980, July 14, 1984, October 19, 1984 and March 13, 1985; and ALARA Program dated April 9, 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed By:

John E. Glenn

By

Nuclear Materials and Safeguards Branch
Region I
King of Prussia, Pennsylvania 19406

Date JUN 11 1985